Abstract
Background Primary Sjogren’s syndrome (pSS) is an autoimmune rheumatic disease affecting the exocrine glands. Several pSS-associated clinical and laboratory parameters may predispose to thromboembolic risk, however clinical data is conflicting. My primary objective was to test whether whole blood clot formation is abnormal in pSS using several complementary approaches: Thromboelestrography (TEG) and Multiplate platelet mapping (MPP) for pSS patients compared to healthy and disease (lupus-SLE) controls and compare the size/composition of blood clots formed ex-vivo between pSS patients and healthy controls using a clotting chamber, which simulates the clotting process in-vivo. My secondary objectives were to determine if any clinical/laboratory/cytokine parameters were associated with abnormal clotting.
Highlights
Primary Sjögren’s syndrome is an autoimmune rheumatic disease affecting the exocrine glands
My primary objective was to test whether whole blood clot formation is abnormal in Primary Sjögren’s syndrome (pSS) using several complementary approaches: Thromboelestrography (TEG) and Multiplate platelet mapping (MPP) for pSS patients compared to healthy and disease controls and compare the size/composition of blood clots formed ex-vivo between pSS patients and healthy controls using a clotting chamber, which simulates the clotting process in-vivo
My secondary objectives were to determine if any clinical/laboratory/cytokine parameters were associated with abnormal clotting
Summary
Assessment of blood clot formation in patients with Primary Sjögren’s syndrome (pSS). K Collins1*, K Balasubramaniam, B Griffiths, G Viswanathan, A Natasari, J Tarn, A Zaman, WF Ng1. From Northern and Yorkshire Deaneries Annual Rheumatology Conference York, UK. From Northern and Yorkshire Deaneries Annual Rheumatology Conference York, UK. 26 September 2012
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have